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have not been systematic studies of its anticancer activity.
Objective: In an effort to enhance the effectiveness of platinum-based drugs, we investigated the
anticancer effect of a Rauwolﬁa vomitoria extract (Rau), both alone and in combination with
carboplatin (Cp).
Methods: In vitro cytotoxicity and colony formation were evaluated in several ovarian cancer cell lines.
In vivo effects were evaluated in an intraperitoneal ovarian cancer mouse model. The combination of Rau
and Cp was assessed using Chou-Talalay’s constant ratio design and median effect analysis based on the
isobologram principle to determine the combination index values.
Results: Rau decreased cell growth in all 3 tested ovarian cancer cell lines dose dependently and
completely inhibited formation of colonies in soft agar. Apoptosis was induced in a time- and dose-
dependent manner and was the predominant form of Rau-induced cell death. Synergy of Rau with Cp
was detected, with combination index values o1 and dose reduction index values for Cp ranging from
1.7- to 7-fold. Tumor growth in mice was signiﬁcantly suppressed by 36% or 66% with Rau treatment
alone at a low (20 mg/kg) or a high dose (50 mg/kg), respectively, an effect comparable to that of Cp
alone. The volume of ascitic ﬂuid and the number of nonblood cells in ascites were also signiﬁcantly
decreased. Combining Rau with Cp remarkably enhanced the effect of Cp and reduced tumor burden by
87% to 90% and ascites volume by 89% to 97%.
Conclusions: Rau has potent antitumor activity and in combination signiﬁcantly enhances the effect of Cp
against ovarian cancer.
& 2013. The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
With an estimated 22,280 new cases and 15,500 deaths in the
United States in 2012, ovarian cancer causes more death than any
other cancer of the female reproductive system.1 Due to the lack of
signiﬁcant symptoms in the early stages and the absence of effective
biomarkers for early detection, ovarian cancer is usually diagnosed
in patients at a late stage of the disease.2–4 As a result, these patients
have a poor prognosis and severely impaired quality of life.
Although current primary therapy can improve the 5-year survivalr Inc.
of Pharmacology, Toxicology,
enter, 3901 Rainbow Blvd.,
Open access under CC BY-NC-ND licerate, it has not increased the overall rate of cure.1,4 This is because
470% of patients experience a relapse and develop a resistance to
platinum- and taxane-based treatments.4,5 Malignant ascites resist-
ant to conventional chemotherapy affect 28% of ovarian cancer
patients in their last period of life.6 Effective and novel treatment
strategies for advanced ovarian cancer are urgently needed.
Numerous studies have attempted to improve the efﬁcacy of
standard platinum-based therapy by incorporating newer cyto-
toxic agents. A promising strategy is to use natural products with
anticancer effects in combination with platinum-based drugs. One
of the advantages of some natural products is their low toxicity
compared with conventional chemotherapy drugs. Combinations
of natural compounds with standard chemotherapy drugs may
exert additive or synergistic effects on killing cancer cells, thereby
allowing lower and safer doses of the more toxic drug to be used.
Herbal preparations of Rauwolﬁa vomitoria, a tropical shrub in
the family of Apocynaceae, have been used in traditional folk
medicine in Africa to treat a variety of ailments including fever,
general weakness, gastrointestinal diseases, liver diseases,nse.
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enriched in β-carboline alkaloids and indole alkaloids.15,16 Many
of these alkaloids have been isolated from the stem, leave, and root
of Rauwolﬁa vomitoria. From the root alone, there are mainly
5 types of 420 alkaloids identiﬁed.15,17–19 Table I listed the main
alkaloids isolated from the Rauwolﬁa vomitoria root. Reserpine, a
drug to control high blood pressure and relieve psychotic symp-
toms, was isolated from the root bark of Rauwolﬁa vomitoria.20–22
Other reported activities of the isolated compounds mainly affect
the neurological and cardiovascular systems, with many of them
not studied for their bioactivities.
The anticancer activities of these components have barely been
studied. One early study in 1986 suggested anti–lymphoma ascites
cells effects of 3 alkaloids, alstonine, serpentine, and sempervirine, in
speciﬁc conditions.23 Another study in 2006 reported on the anti–
prostate cancer activity of Rauwolﬁa vomitoria, but the active anti-
cancer component in the extract was not known.24 Apart from the
investigations of its components, the extract as a whole is widely
used and actively studied. The extract of this medical herb as a whole
mixture has been a traditional medicine for 42000 years in Africa
for the treatment of hypertension and mental disorders. The effec-
tiveness has been conﬁrmed in more recent studies to be mainly as
antipsychotic, antihypertensive, anti-inﬂammatory and improving
blood chemistry. A Rauwolﬁa-citrus tea is in an early phase clinical
trial in Denmark for its antidiabetic effect.7 In this study, we
evaluated an important but not yet well-understood aspect of the
effect of an extract from the root of Rauwolﬁa vomitoria, enriched
with alkaloids and with reserpine removed, in the treatment of
ovarian cancer, used alone and in combination with carboplatin (Cp).Materials and Methods
Experimental materials, cell lines, and cell viability assay
Human ovarian cancer cell lines OVCAR-5 and OVCAR-8 were
obtained from the American Type Culture Collection (Manassas,
Virginia), SHIN-3 was donated by Dr. Perter Eck at the National
Institutes of Health.25 Immortalized human lung epithelial cells
MRC-5 were provided by Dr. Sittampalam at the University of
Kansas Medical Center and were compared with cancer cells. AllTable I
Major alkaloids and their bioactivities isolated from the root of Rauwolﬁa vomitoria.
Type Alkaloids Detected Activities Reported
Yohimbine α-Yohimbine Pre- and postsynaptic α2-ad
18-Hydroxy-yohimbine Reserpine Antipsychotic, antihypertens
Rescinnamine Antihypertension
Heteroyohimbine Aricine Unknown
Reserpiline Antipsychotic, antigastric se
Isoreserpiline Antipsychotic
Dihydroindole Sarpagine Unknown
Ajmaline Antiarrhythmia, antiﬁbrillati
Sandwicine Unknown
Iso-sandwicine Unknown
Mitoridine Unknown
Rauvomitine Unknown
N-demethyl-rauvomitine Unknown
Purpeline Unknown
Seredamine Unknown
Suaveoline Unknown
Tetraphyllicine Myocardial excitation
Vomalidine Unknown
Serpentine Antioxidant, possible antican
Alstonine Antipsychotic, possible antic
Ψ-Indoxyl Isoreserpiline- Ψ-indoxyl Unknown
Oxindole Carapanaubine Unknown
Rauvoxine Unknownthe cells were cultured at 371C in 5% CO2/95% air in recommended
growth media containing 10% fetal calf serum.
Rauwolﬁa vomitoria extract (Rau) was provided by Natural Source
International (New York, New York). The extract was prepared from
air-dried clean roots of Rauwolﬁa vomitoria, ﬁrst powdered with an
electric blender and then extracted twice with 80% ethanol, accord-
ing to a reported method.26 From the extract, reserpine was
removed by chloroform extraction conducted efﬁciently in columns.
Quality control was ensured by HPLC. All the experiments used the
extract from a single lot. Rau and Cp (Sigma, St. Louis, Missouri)
were prepared in sterile water and stored at −201C.
Cells were tested for viability by the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay at 48 hours of
treatment. Cells in the exponential growth phase were exposed
to serial dilutions of Rau, Cp, or a combination of the two for 48
hours. The incubation time was determined by pre-experiments to
obtain the optimal cell death effect. Then cells were changed to
fresh media containing MTT and incubated for 4 hours. The
colorimetric MTT assay assessed relative proliferation, based on
the ability of living, but not dead, cells to reduce MTT to
formazan.27,28 Cells did not reach the plateau phase during the
incubation period. IC50 was deﬁned as the concentration of drug
that inhibited cell growth by 50% relative to the untreated control.
Anchorage-independent colony formation assay
Anchorage-independent colony formation assays in soft agar
were used to determine long time survival of tumorigenic cancer
cells after treatments. In 6-well plates, SHIN-3 cells (5000 cells per
well) were seeded in the upper layer containing 0.5% agar,
Dulbecco’s modiﬁed Eagle medium, and 10% fetal bovine serum,
with or without 400 μg/mL Rau. The solid agar base (lower layer)
contained 0.75% agar and complete growth medium, with or
without 400 μg/mL Rau, respectively. After 20 days of incubation,
colonies were visualized by crystal violet staining, and the number
of colonies was counted.
Apoptosis detection by ﬂow cytometry
Cells were exposed to various concentrations of Rau for 48 hours.
Cells were washed in phosphate-buffered saline, resuspended inReference
renoceptor inhibitor, stimulant and aphrodisiac effect, antidiabetic 41,42
ion, antidepression, anticancer, carcinogenesis 43–48
49
cretion, antihypertension 50–53
8,53
on, cardiac and liver toxicity 54,55
56
cer 23,40
ancer 23
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jugated annexin V and propidium iodide (PI) staining according to
the manufacturer’s protocol (BD Biosciences, San Jose, California).
Cells were analyzed by ﬂow cytometry. Annexin V–positive and
annexin V-PI double–positive cells were identiﬁed as apoptotic
cells, whereas PI single–positive cells were identiﬁed as
necrotic cells.
Western blot
Forty micrograms of protein were loaded for SDS-PAGE.
Primary and secondary antibodies were from Cell Signaling Tech-
nology Inc. (Danvers, Massachusetts): rabbit anti–poly (ADP-
ribose) polymerase (PARP) (1:2000), rabbit anti-caspase-3
(1:1000), rabbit anti-capase-8 (1:1000), mouse anti-β-actin
(1:1000), and goat anti-rabbit or anti-mouse immunoglobulin G
(1:5000). Blots were developed using immobilon chemilumines-
cent substrate (Thermo Scientiﬁc, Waltham, Massachusetts).
Intraperitoneal ovarian cancer mouse model
Nude mice were injected with SHIN-3 cells by intraperitoneal
injection (2.6  106/mouse). Seven days after tumor cell inocu-
lation, treatment began with intraperitoneal injection of Cp
(15 mg/kg weekly), Rau (20 or 50 mg/kg/d), the respective
combination of Cp and Rau, and saline solution as control. After
23 days of treatment, mice were euthanized. All tumor lesions in
the peritoneal cavity were collected and weighed; ascites were
collected, and nonblood cells were counted in ascitic ﬂuids as an
index of tumor cells in the ﬂuids. Major organs such as the liver,
kidney, and spleen were ﬁxed in formaldehyde and subjected to
histological analysis for any damage caused by potential drug
toxicity.
Data analysis
MTT data were normalized to their corresponding untreated
controls for each condition (drug, cell type) and were expressed as
a percentage of viability. Dose-reduction index (DRI) values for Cp
were calculated by the equation DRIICx ¼ (DCp/DCpþRau), where
DCp is the dose of Cp alone required to produce an ICx level of
cytotoxicity, and DCpþRau is the dose of Cp needed to produce the
same ICx level of cytotoxicity when it is combined with Rau (at a
given molar ratio). DRICp is deﬁned with respect to Cp. Combina-
tion index (CI) values were calculated by the equa-
tion CIICx ¼ (DCpCombo ICx/DCp ICx) þ (DRauCombo ICx/DRau ICx) þ
α[(DCpComboICx)(DRauComboICx)/(DCp ICx)(DRau ICx)], where D is theFig. 1. Cytotoxicity of Rauwolﬁa vomitoria extract (Rau) in normal cells and ovarian cance
cells SHIN-3, OVCAR-5, and OVCAR-8 were exposed to serial concentrations of Rau fo
diphenyltetrazolium bromide (MTT) assay. A noncancerous epithelial cell, MCR-5, was s
inhibited cell growth by 50% relative to the untreated control. (*P o 0.05 relative to a
without Rau treatment. Five thousand SHIN-3 cells per well in 6-well plates were either t
7 SD of 3 independent experiments.dose of Cp and Rau, either alone or in combination, at a given
constant ratio required to produce an ICx level of cytotoxicity.29–31
The more conservative assumption of mutual exclusivity was
adopted (α ¼ 0). SPSS version 15.0 (SPSS Inc., Chicago, Illinois)
was used for additional statistical analysis.Results
Inhibition of ovarian cancer cell viability and colony formation by Rau
Human ovarian cancer cell lines (SHIN-3, OVCAR-5, and OVCAR-8)
were subjected to Rau treatment to test for sensitivity at concen-
trations from 0 to 800 mg/mL. An immortalized nontumorigenic
epithelial cell line (MRC-5) was subjected to the same treatment for
comparison. The dose-response curves showed that all cancer cells
were susceptible to Rau treatment with IC50 values of ∼300 mg/mL,
whereas the immortalized noncancerous cells MRC-5 was less
sensitive with IC50 ¼ 566 mg/mL, a signiﬁcant difference compared
with cancer cells (Figure 1A). At a concentration of 400 mg/mL, Rau
was able to reduce cell viability by 60% to 80% in all 3 tested ovarian
cancer cells and only decreased viability in MRC-5 cells by 28%.
Colony formation in soft agar was used to assess the drug effect
on tumor cell survival for a longer time, as well as to assess the
survival of tumorigenic cells, which are important for in vivo
tumor formation.32,33 Untreated SHIN-3 cells formed colonies in
soft agar at a rate of 23%. Rau at 400 mg/mL completely inhibited
formation of colonies of SHIN-3 cells in soft agar (Figure 1B),
indicating no survival of tumorigenic cancer cells with this
treatment.
Induction of apoptosis in ovarian cancer cells by Rau
To assess the Rau-induced death pathway, annexin V/PI strain-
ing was performed to detect apoptosis versus necrosis in SHIN-3
cells treated with Rau. Data from ﬂow cytometry demonstrated
that predominant apoptosis was induced by Rau treatment. With
0, 50, 100, and 400 μg/mL Rau treatment, the percentage of
positive cells with annexin V and PI straining were 5.7%, 33.6%,
49.6%, and 85.3% respectively (Figure 2A). The induction of
apoptosis was clearly dependent on the concentration of Rau with
a logarithmic relationship (Figure 2A) and was the major form of
cell death induced by Rau. Necrosis (cells that were PI positive
only) contributed only 6% to 14% of total cell death all across the
Rau concentrations.
Consistent with this ﬁnding, Western blot analysis detected
extensive cleavage of caspase-8, caspase-3, and PARP in Rau-treatedr cells. (A) Dose-response curves of normal and ovarian cancer cells. Ovarian cancer
r 48 hours, and cell viabilities were detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-
ubjected to the same treatment. IC50 was deﬁned as the concentration of drug that
ny of the cancer cells). (B) Colony formation of SHIN-3 cells in soft agar with and
reated with 400 μg/mL Rau or untreated (Control). All values are expressed as mean
Fig. 2. Apoptosis in SHIN-3 cells induced by Rauwolﬁa vomitoria extract (Rau). (A) Flow-cytometry detection of apoptotic cells. SHIN-3 cells were treated with 400 μg/mL of
Rau for 48 hours and then underwent double staining with ﬂuorescein isothiocyanate–conjugated annexin V and propidium iodide. The rate of apoptosis was represented by
the percentage of cells in the Q2 and Q4 quadrants. A logarithmic relationship between the apoptosis rate and concentration of Rau was shown. (B) Cleavage of caspases and
poly(ADP-ribose) polymerase (PARP) in SHIN-3 cells treated with Rau. Cells were treated with Rau at the indicated concentrations and time. The dose-dependent and time-
dependent cleavage of caspase-8, caspase-3, and PARP were detected by Western blot. β-Actin acted as a loading control.
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(Figure 2B).
Synergy of Rau in combination with Cp against ovarian cancer cells
As platinum-based treatment is a current primary care for
ovarian cancer patients, the effect of the combination of Rau and
Cp was examined using cultured ovarian cancer cells. After deter-
mining the dose-response relationships for Rau (Figure 1A), the
dose-response relationships for Cp cytotoxicity were established in
SHIN-3, OVCAR-5, and OVCAR-8 cells (Figure 3A, dotted lines). A
constant ratio design was used to systematically examine combina-
tion dose-response relationships between Cp and Rau. The ratio of
Cp to Rau was chosen as IC50Cp:IC50Rau. Combination data were
presented in terms of Cp concentration. Despite the inherent
sensitivity to Cp, results clearly showed that when Rau was added
to Cp, decrease in cell viability was dramatically enhanced in all
tested cells compared with Cp as a single agent (Figure 3A).
The CI value for each cell type was calculated relying on Chou-
Talalay’s isobologram principle to determine whether drug combina-
tions were synergistic (CI o1), additive (CI ¼ 1), or antagonistic
(CI 41).28–30 In addition, DRI value for Cp was calculated as described
in the Material and Methods section. DRI values 41 indicate a
favorable combination, whereas a DRI value o1 would be interpretedas an antagonistic combination. In all cell lines tested, CI values were
≤1 (Figure 2B), and DRI values for Cp were 41 (Figure 2C) across the
desired levels of effect (fa, fraction affected). This indicated an additive
to synergistic effect when Rau was combined with Cp. Reduction in
Cp doses ranged from 1.7- to 7-fold when Rau was combined with Cp,
depending on cell lines and the aimed level of effect. These data
unequivocally support the conclusion that the concentration of Cp can
be decreased to produce an equitoxic effect on ovarian cancer cells
when Rau is combined with Cp.
In vivo tumor inhibitory effect of Rau alone or in combination with Cp
An intraperitoneally implanted SHIN-3 mouse xenograft model
was used to evaluate the effect of Rau and the combination of Cp
and Rau (Cp þ Rau) treatment. Compared with the subcutaneous
implantation model, the intraperitoneal model better mimics the
clinical condition of advanced human ovarian cancer, especially in
peritoneal metastasis and ascites formation. Tumor-bearing mice
were treated for 23 days, and necropsy was performed at eutha-
nasia. All tumor lesions in the peritoneal cavity were collected and
examined, as was ascitic ﬂuid.
As shown in Figure 4A, Rau treatment alone decreased total
tumor weight by 36% and 66% at the daily dose of 20 mg/kg or
50 mg/kg, respectively, compared with saline solution–treated
Fig. 3. Combination effect of Rauwolﬁa vomitoria extract (Rau) and carboplatin (Cp) in ovarian cancer cells. (A) Dose-response curves. Ovarian cancer cells were treated with
Cp (dotted line) and the combination of Cp and Rau (Cp þ Rau, solid line) for 48 hours. The molar ratio of the combination was IC50Rau:IC50Cp. (B) Combination index (CI)
across the fraction affected (fa). The molar ratio of Rau:Cp was IC50Rau:IC50Cp. A CI value 41 indicates antagonism, a CI value of 1 indicates additive effect, and a CI value o1
indicates synergy. (C) The dose-reduction index (DRI) across the fa for Cp when Rau was combined.
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By combining Rau with Cp, the tumor inhibitory effect was
dramatically enhanced. Tumor weight decreased 87% (Cp þ
20 mg/kg Rau) and 90% (Cp þ 50 mg/kg Rau) relative to control.Fig. 4. Effect of Rauwolﬁa vomitoria extract (Rau) and the combination of Rau and carbo
Cells (2.6  106) were intraperitoneally injected into nude mice. After 7 days of tum
20 mg/kg/d (Rau20) or 50 mg/kg/d (Rau50), Cp at 15 mg/kg/wk, and respective combina
tumor weight, volume of ascites, and number of cells in ascites were assessed at the en
nonblood cells in the ascitic ﬂuids. (D) Cleavage of capase-3 and poly(ADP-ribose) polym
and eosin staining of major organs from different treatment group (400 magniﬁcation)
formaldehyde and later underwent histological analysis. (*P o 0.05, **P o 0.01, ***P o
Cp-treated group.)The enhancement was signiﬁcant compared with either Rau or Cp
single-agent treatment.
Excessive volumes of ascites were formed in saline solution–
treated control mice at the endpoint of the experiment (4 mL ofplatin (Cp) against SHIN-3 ovarian cancer cells in an intraperitoneal mouse model.
or inoculation, treatment commenced with an intraperitoneal injection of Rau at
tions of Rau and Cp (CpþRau20, and CpþRau50). Treatment lasted for 23 days, and
d of treatment. (A) Total tumor weight. (B) Volume of ascitic ﬂuids. (C) Number of
erase (PARP) in tumor samples from different treatment groups. (E) Hematoxylin
. Kidney, liver, and spleen were collected from each treatment group and ﬁxed in 4%
0.001 relative to control group; #P o 0.05, ##Po 0.01, ###P o 0.001 relative to
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decreased the volume of ascitic ﬂuid to an average of 2.3 mL per
mouse at the dose of 20 mg/kg and to 1.5 mL per mouse at the
dose of 50 mg/kg (P o 0.05). The degree of reduction is
comparable to that of Cp (Figure 4B). By combining Rau with Cp
(20 or 50 mg/kg Rau), the combination treatments decreased
ascites volume by 89% and 97% compared with control to a
minimal amount of 0.44 mL per mouse and 0.13 mL per mouse
(Figure 4B).
Nonblood cells in ascitic ﬂuid were counted as an estimation of
tumor cells in the ascites. The results were shown as the number
of cells per milliliters of ascites. Although Cp at the doses used did
not reduce the number of cells in ascites, Rau showed a strong
effect in decreasing the number of cells per milliliters of ascites by
43% and 75%. Moreover, when combined with Cp, Rau at either of
the doses used decreased the number of cells per milliliters of
ascites by 98% (Figure 4C).
Proteins were isolated from tumor samples of the treated
and control mice. Western blot analysis showed cleavage of
caspase-3 and PARP in Rau and Cp þ Rau treatment groups at
either high or low doses of Rau (Figure 4D), whereas Cp treatment
alone did not cause cleavage in caspases and PARP. These results
conﬁrmed the in vitro data that Rau induced apoptosis in
tumor cells.
None of the mice demonstrated observable toxicity asso-
ciated with the treatments. At the end of the experiments, major
organs (kidney, liver, and spleen) were underwent hematoxylin
and eosin staining and histological analysis. No tissue damage
was detected in the treatment groups, and there were no signiﬁ-
cant differences between control group and treated groups
(Figure 4E).Discussion
Inherent or acquired drug resistance has been a serious prob-
lem in ovarian cancer therapy. Combining platinum-based chemo-
therapy with other anticancer drugs has been an effective way to
improve therapeutic outcome.34–36 Rauwolﬁa vomitoria has been a
folk medicine for centuries, and its extract has been shown to
provide antioxidant and antiproliferative effects in different sys-
tems based on its inhibition of diverse cellular events associated
with tumor pathogenesis.23,24,37 Our data demonstrated that Rau
substantially inhibited ovarian cancer cell growth, both in vitro
and in vivo. Despite the inherent Cp sensitivity of the cell lines,
Rau increased chemosensitivity of all tested ovarian cancer cells
and synergized with Cp in the inhibition of ovarian cancer.
Importantly, Rau inhibited the tumor growth in a mouse model
with intraperitoneal metastasis and massive ascites formation,
either alone or in combination with Cp. With Rau and Cp
combination treatment, a remarkable tumor inhibition of 490%
was achieved, and the ascites were nearly eradicated. This effect
was not achieved by Cp treatment alone. It is possible that
different degrees of additive/synergistic effects will be achieved
if conditions of combination are different, such as the doses of
both drugs to be combined, the time and order of administration,
and the intervals of treatment. The study here provides a basis for
further investigation in reﬁning the combination regimen to
achieve optimal effects, even possible complete tumor inhibition.
As the prognosis and survival rate are poor for ovarian cancer
patients who have intraperitoneal metastasis,1 these results pro-
vided a basis for further investigation for Rau as an adjuvant
treatment for ovarian cancer patients.
Moreover, our data showed that Rau had relatively low toxicity
on normal cells. This was evident in mice treated with Rau in
which major organ toxicities were absent. As many studies havereported psychological and cardiovascular activities of Rau, the
anticipated toxic side effects could be hypotension, cardiac toxicity,
psychological effects, and gastrointestinal disturbance. However,
in our extract, the compound reserpine was removed, which is the
main contributor to the hypotensive effect and part of the
psychological effects. Therefore, low toxicity with our extract could
be expected. Consistent with this hypothesis, no abnormalities or
toxic signs were observed in the mice. In summary, the antitumor
activities of Rau synergizing with Cp suggest that this herbal
preparation could potentially offer therapeutic beneﬁt in the
management of ovarian cancer.
Although potential beneﬁt was suggested by our study, the
mechanism(s) of Rau that induced an anticancer effect warrant
further study. A previous study reported DNA damage and cell
cycle inhibition induced by Rau in prostate cancer cells.24 Activa-
tion of these pathways could lead to apoptosis, which is a powerful
tumor-suppressive pathway preventing the uncontrolled prolifer-
ation of cancerous cells and potentially depleting stemlike and
progenitor cancer cell pools.38,39 Consistent with these reports, our
study showed that Rau mainly induced apoptosis in vitro and
in vivo, as shown by ﬂow cytometry and the cleavage of caspase-8,
caspase-3, and PARP. The in vitro tumorigenic capacity of ovarian
cancer cells was completely inhibited by Rau treatment. However,
because this plant preparation contains a complex mixture of
natural compounds, there is potential to affect multiple molecular
targets and pathways.
Bioactive compounds are often found in medicinal plant and
herbal mixtures, making them a superb source for the discovery of
novel drug leads. The β-carboline– and indole alkaloid–enriched
Rau appears to contain components that possess potent anticancer
activity. Our study demonstrated for the ﬁrst time the anticancer
and chemo-potentiation activity of the mixture of Rau in ovarian
cancer, with novelty and signiﬁcance. Because its anticancer
components are largely unknown, it is possible to trace the
anticancer activity to single compound, such as alstonine and/or
serpentine.23,40 On the other hand, there is also the possibility that
several components work in concert to exhibit optimal anticancer
activity and lower toxicity, such as that seen in many herbal
medicines and traditional Chinese medicines. Also, a nonlinear or
U-shape dose-response in vivo has been reported by other inves-
tigators, further suggesting that different components in the
extract were working together.24 Although further studies are
needed to investigate these interesting questions, the data pre-
sented here provide a basis for identifying the anticancer activity
of Rau. Active components could be isolated and developed for
optimizing the efﬁcacy, toxicity, and other proﬁles that could lead
to anticancer drug development.Acknowledgments
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